Restart Apixaban (Eliquis) After Hip Fracture Repair
For a patient on chronic apixaban for atrial fibrillation who undergoes hip fracture repair, restart apixaban postoperatively rather than switching to enoxaparin—this provides both VTE prophylaxis and necessary stroke prevention for the underlying atrial fibrillation indication.
Rationale Based on Guidelines and Evidence
The 2022 AAOS hip fracture guidelines strongly recommend VTE prophylaxis for all hip fracture patients 1. The critical distinction in your case is that this patient was already on apixaban for atrial fibrillation, not just for VTE prophylaxis.
Key Decision Points:
Dual Purpose of Anticoagulation:
- This patient requires anticoagulation for two separate indications: stroke prevention (atrial fibrillation) and VTE prophylaxis (hip fracture surgery)
- Enoxaparin only addresses VTE prophylaxis and leaves the patient unprotected against stroke
- The 2022 CHEST perioperative guidelines support resuming DOACs like apixaban approximately 24 hours after low-to-moderate bleeding risk procedures, or 48-72 hours after high-bleeding-risk procedures 2
Timing of Restart:
- The AAOS case example specifically demonstrates restarting apixaban on postoperative day 2 in a similar patient with atrial fibrillation who underwent hip arthroplasty 1
- This timing balances surgical hemostasis with thrombotic risk
Efficacy Evidence:
- Multiple studies demonstrate apixaban is superior to enoxaparin for VTE prophylaxis after hip replacement, with lower VTE rates (1.4% vs 3.9%, p<0.001) and similar bleeding profiles 3
- Pooled analysis of 8,464 patients showed major VTE occurred in 0.7% with apixaban vs 1.5% with enoxaparin (p=0.001), without increased bleeding 4
Practical Implementation
Recommended Approach:
- Hold apixaban preoperatively (typically 24-48 hours before surgery depending on renal function and bleeding risk)
- Restart apixaban 2.5 mg twice daily on postoperative day 1-2 once hemostasis is established
- Continue for 35 days post-hip fracture surgery (standard duration for hip procedures)
- Then transition back to the patient's chronic atrial fibrillation dose (typically 5 mg twice daily, or 2.5 mg twice daily if dose-adjusted)
Common Pitfalls to Avoid:
- Don't switch to enoxaparin unless there are specific contraindications to apixaban (severe renal impairment with CrCl <15 mL/min, active major bleeding)
- Don't forget the patient needs lifelong anticoagulation for atrial fibrillation—enoxaparin is only temporary and creates a gap in stroke prevention
- Monitor renal function closely, as the case example notes a creatinine of 1.42 mg/dL—apixaban dosing may need adjustment if CrCl <30 mL/min
- Ensure hemostasis before restarting—wait 48-72 hours if there are concerns about surgical bleeding
When Enoxaparin Might Be Preferred:
Enoxaparin would only be the better choice if:
- Severe renal impairment (CrCl <15 mL/min) where apixaban is contraindicated
- Active bleeding or very high bleeding risk requiring shorter-acting anticoagulation
- Patient unable to take oral medications
- Need for neuraxial anesthesia/epidural (requires longer DOAC interruption)
The FDA labeling confirms enoxaparin 30 mg every 12 hours or 40 mg once daily is effective for hip fracture surgery 5, but this doesn't address the atrial fibrillation indication that apixaban serves.